Zac Sweeney

Zac Sweeney covers the companies and market structures shaping the ASX and SGX, with particular attention to mining, MedTech and pharma. These are sectors where a small listed company can sit close to a significant theme: critical minerals and supply-chain security, new tools for diagnosis and treatment, or therapies seeking a path from research to commercialisation. For investors, the challenge is separating meaningful progress from ambitious presentations and distant potential.

His mining coverage looks beyond commodity headlines to the details that can determine whether a project advances: the quality and location of a resource, access to infrastructure, permitting, funding needs, offtake arrangements and exposure to commodity prices. Critical minerals have attracted government and industrial attention because processing and supply are concentrated in relatively few regions, but the strategic importance of a mineral does not remove the technical, financial and execution risks facing a small-cap developer.

In MedTech and pharma, Zac follows the evidence behind the story. That means examining clinical and regulatory milestones, trial design, intellectual property, reimbursement prospects, manufacturing requirements and the partnerships that can help a product reach patients. Smaller healthcare companies are often difficult to assess because value can hinge on a handful of studies, approvals or commercial agreements; clear reporting can help readers understand what has been demonstrated, what remains uncertain and which milestones matter next.

Zac also tracks listed option arbitrage, where differences between securities, conversion terms, expiry dates and market prices can create questions about how a company’s capital structure is being valued. His coverage is designed for readers who want more than a ticker and a headline: careful attention to announcements, financial incentives, dilution, liquidity and the assumptions behind a market narrative. In markets where smaller companies may receive less analyst coverage, that focus can bring useful context to developments that might otherwise pass unnoticed.